Remus Pharmaceuticals (NSE:REMUS) Institutional Ownership: 0.00% (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
56 GF Score
Price ₹720.00
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Institutional Ownership?

Remus Pharmaceuticals NSE:REMUS +0.33% 56 Institutional Ownership is 0.00% as of Aug. 01, 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 56/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Remus Pharmaceuticals's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Remus Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Remus Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Remus Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Institutional Ownership Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Institutional Ownership
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Institutional Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:REMUS
56GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.00% mean?
Remus Pharmaceuticals (NSE:REMUS) has a Institutional Ownership of 0.00% as of Aug. 01, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Institutional Ownership too high?
Remus Pharmaceuticals' current Institutional Ownership is 0.00%. Overall, Remus Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Institutional Ownership compare to MCK and COR?
Remus Pharmaceuticals' Institutional Ownership of 0.00% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Distribution company?
A good Institutional Ownership depends on the Medical Distribution industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Institutional Ownership is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹720.00 — trading 65.2% below its estimated fair value. The current Institutional Ownership is 0.00%. Remus Pharmaceuticals' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Institutional Ownership is 0.00% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹720.00 is trading 65.2% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Institutional Ownership: 0.00%
  • GF Value™: ₹2,071.36 vs. price of ₹720.00 (65.2% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
56GF Score

Get the complete analysis for NSE:REMUS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹720.00
Price
₹2,071.36
GF Value